Marks Group Wealth Management Inc Has $1.61 Million Stake in GSK plc (NYSE:GSK)

Marks Group Wealth Management Inc trimmed its stake in shares of GSK plc (NYSE:GSK) by 10.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 43,488 shares of the pharmaceutical company’s stock after selling 5,250 shares during the period. Marks Group Wealth Management Inc’s holdings in GSK were worth $1,612,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Versant Capital Management Inc increased its stake in GSK by 2,816.7% in the 4th quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock valued at $26,000 after buying an additional 676 shares during the last quarter. BKM Wealth Management LLC acquired a new stake in GSK in the 4th quarter valued at $32,000. Larson Financial Group LLC grew its position in shares of GSK by 271.8% in the 3rd quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 647 shares during the period. Jones Financial Companies Lllp grew its position in shares of GSK by 62.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock valued at $48,000 after acquiring an additional 509 shares during the period. Finally, Washington Trust Advisors Inc. bought a new stake in shares of GSK during the 3rd quarter worth about $53,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Price Performance

Shares of NYSE:GSK traded up $0.55 during midday trading on Tuesday, hitting $41.14. The stock had a trading volume of 1,283,992 shares, compared to its average volume of 3,457,616. The company’s 50-day moving average price is $41.88 and its 200-day moving average price is $38.86. The company has a market capitalization of $85.26 billion, a P/E ratio of 13.49, a price-to-earnings-growth ratio of 1.40 and a beta of 0.64. GSK plc has a fifty-two week low of $33.33 and a fifty-two week high of $43.84. The company has a quick ratio of 0.62, a current ratio of 0.88 and a debt-to-equity ratio of 1.19.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). The company had revenue of $10 billion for the quarter, compared to analyst estimates of $9.79 billion. GSK had a return on equity of 51.45% and a net margin of 16.24%. As a group, equities research analysts predict that GSK plc will post 4.03 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, April 11th. Shareholders of record on Friday, February 23rd were given a $0.3564 dividend. This is a boost from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 annualized dividend and a yield of 3.46%. The ex-dividend date of this dividend was Thursday, February 22nd. GSK’s dividend payout ratio is 52.82%.

Analyst Ratings Changes

Several brokerages recently commented on GSK. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. Citigroup raised shares of GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. Jefferies Financial Group raised shares of GSK from a “hold” rating to a “buy” rating in a report on Wednesday, January 3rd. Finally, Morgan Stanley initiated coverage on shares of GSK in a report on Tuesday, January 23rd. They issued an “equal weight” rating for the company. One analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GSK presently has a consensus rating of “Moderate Buy”.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.